Product
QL2109
1 clinical trial
1 indication
Indication
TumorClinical trial
A Randomized, Double-blind, Single-dose, Parallel Study to Compare the Pharmacokinetics and Safety of QL2109 and DARZALEX FASPRO® in Healthy Male AdultsStatus: Not yet recruiting, Estimated PCD: 2025-04-01